✦ LIBER ✦

A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignancies

✍ Scribed by Cynthia Ma; Sumithra J. Mandrekar; Steven R. Alberts; Gary A. Croghan; Aminah Jatoi; Joel M. Reid; Lorelei J. Hanson; Laura Bruzek; Angelina D. Tan; Henry C. Pitot; Charles Erlichman; John J. Wright; Alex A. Adjei

Book ID: 105992420
Publisher: Springer
Year: 2006
Tongue: English
Weight: 310 KB
Volume: 59
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-006-0259-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of the proteasome inhibit

Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade®) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)

✍ Li, Tianhong; Ho, Liawaty; Piperdi, Bilal; Elrafei, Tarek; Camacho, Fernando J.; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 240 KB

Phase I combination trial of gemcitabine

Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy

✍ Keith T. Flaherty; James P. Stevenson; Stephen M. Hahn; Maryann Redlinger; Peter 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 178 KB

Phase I trial of the proteasome inhibito

Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer

✍ Pedro T. Ramirez; Charles N. Landen Jr.; Robert L. Coleman; Michael R. Milam; Ch 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 125 KB

A phase I, open label, dose-escalating s

A phase I, open label, dose-escalating study of the proteasome inhibitor PS-341 (VELCADE¢) in combination with two schedules of trastuzumab, in patients with advanced breast cancer (ABC) that overexpresses HER-2

✍ F. Cardoso; Azambuja; C. Bernard; L. Dirix; D. De Becker; S. Bartholomeus; V.D H 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 125 KB

Phase I and pharmacokinetic study of BMS

Phase I and pharmacokinetic study of BMS-247550 in combination with carboplatin in patients with advanced malignancies

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 124 KB

P-245 The proteasome inhibitor, bortezom

P-245 The proteasome inhibitor, bortezomib, in combination with gemcitabine (gem) and carboplatin (carbon) in advanced non-small cell lung cancer (NSCLC): A phase I study

✍ Davies, Angela; Lara, Primo N.; Mack, Philip C.; Gumerlock, Paul H.; Turrell, Co 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 178 KB